Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 4.65 a new company low.

Within Biotechnology & Pharmaceuticals industry 62 other companies have achieved higher Quick Ratio than Agomab Therapeutics Nv in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 638.

Explain Quick Ratio?
How much Cash & cash equivalents AGMB�s has?
What are AGMB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AGMB/financial-strength

https://api.csimarket.com/api/v1/companies/AGMB/fundamentals

https://api.csimarket.com/api/v1/companies/AGMB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

AGMB Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1
Y / Y Current Liabilities Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.65	Subscribe	Subscribe	Subscribe	Subscribe
AGMB's Total Ranking	# 638	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 63
Healthcare Sector	# 294
Overall Market	# 638

Quick Ratio Statistics
High	Average	Low
4.65	4.65	4.65
(Dec 31 2025)

Financial Statements
Agomab Therapeutics Nv's Current Liabilities	$ 21 Millions	Visit AGMB's Balance sheet
Agomab Therapeutics Nv's Cash & cash equivalent	$ 97 Millions	Visit AGMB's Balance sheet
Source of AGMB's Sales		Visit AGMB's Sales by Geography

Cumulative Agomab Therapeutics Nv's Quick Ratio

AGMB's Quick Ratio for the trailling 12 Months

AGMB Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.65	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	#	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	33.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	33.33 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to AGMB Financial Strength Comparisons >> Go to Compare AGMB Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the unchanged in Current Liabilities in the Q4 2025 to $20.82 millions, cumulative Quick Ratio remained unchanged at 4.65 below the Agomab Therapeutics Nv average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 62 other companies have achieved higher Quick Ratio than Agomab Therapeutics Nv. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents AGMB�s has?
What are AGMB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 63
Healthcare Sector	# 294
Within the Market	# 638

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.65	4.65	4.65
(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Vaxcyte Inc	12.49	$ 1,560.959 Millions	$ 124.972 Millions
Kalaris Therapeutics Inc	12.15	$ 117.982 Millions	$ 9.714 Millions
Imagenebio Inc	12.05	$ 135.349 Millions	$ 11.234 Millions
Taysha Gene Therapies Inc	12.04	$ 319.767 Millions	$ 26.552 Millions
Engene Therapeutics Inc	11.21	$ 275.948 Millions	$ 24.609 Millions
Genenta Science S p a	10.87	$ 39.465 Millions	$ 3.630 Millions
Cullinan Therapeutics Inc	10.22	$ 377.896 Millions	$ 36.961 Millions
X4 Pharmaceuticals Inc	9.82	$ 252.998 Millions	$ 25.757 Millions
4d Molecular Therapeutics Inc	9.15	$ 402.655 Millions	$ 43.985 Millions
Prokidney Corp	9.10	$ 270.017 Millions	$ 29.671 Millions
Sab Biotherapeutics Inc	9.04	$ 96.592 Millions	$ 10.681 Millions
Denali Therapeutics Inc	8.82	$ 867.879 Millions	$ 98.351 Millions
Artiva Biotherapeutics Inc	8.25	$ 108.008 Millions	$ 13.087 Millions
Black Diamond Therapeutics Inc	8.18	$ 128.652 Millions	$ 15.731 Millions
Zura Bio Limited	8.02	$ 109.407 Millions	$ 13.647 Millions
Molecular Partners Ag	7.86	$ 104.149 Millions	$ 13.254 Millions
Aura Biosciences Inc	7.85	$ 144.241 Millions	$ 18.383 Millions
Allogene Therapeutics Inc	7.70	$ 250.210 Millions	$ 32.514 Millions
Compugen Ltd	7.67	$ 145.640 Millions	$ 18.999 Millions
Voyager Therapeutics Inc	7.40	$ 196.447 Millions	$ 26.541 Millions
Scholar Rock Holding Corp	7.37	$ 367.563 Millions	$ 49.869 Millions
Krystal Biotech Inc	7.27	$ 827.791 Millions	$ 113.861 Millions
Metagenomi Therapeutics Inc	7.01	$ 160.799 Millions	$ 22.933 Millions
Fennec Pharmaceuticals Inc	7.00	$ 73.576 Millions	$ 10.518 Millions
Odyssey Therapeutics, Inc.	6.85	$ 181.358 Millions	$ 26.475 Millions
Invivyd Inc	6.64	$ 226.689 Millions	$ 34.163 Millions
Entera Bio Ltd	6.59	$ 7.108 Millions	$ 1.079 Millions
Tenaya Therapeutics Inc	6.51	$ 100.547 Millions	$ 15.436 Millions
Repligen Corp	6.51	$ 767.628 Millions	$ 117.859 Millions
Cardiol Therapeutics inc	6.16	$ 15.619 Millions	$ 2.537 Millions

Date modified: 2026-04-24T15:30:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.